

PHARMACY BENEFIT PRIOR AUTHORIZATION UPDATES

March 24th, 2023

Below are upcoming updates to pharmacy benefit medication prior authorization criteria for Community Health Choice's Marketplace plans.

Marketplace Premier Plans

Drug/Class	Effective Date	Overview
Tukysa	4/1/2023	Adding new indication for colorectal cancer
Brukinsa	4/1/2023	Adding new indication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
adapalene/benzoyl peroxide 0.1-2.5%/0.3-2.5% gel	4/1/2023	Removing PA
benznidazole	4/1/2023	Removing PA
Amjevita (adalimumab biosimilar) / Humira	4/1/2023	Adding Amjevita (adalimumab biosimilar) to the formulary with PA; Adding Amjevita to the Humira PA form
Cimzia	4/1/2023	Adding Amjevita (adalimumab biosimilar) for any indications where Cimzia steps through adalimumab with its addition to the formulary
Zeposia	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Orencia	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Olumiant	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Simponi 100 mg	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Kevzara	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Actemra subq injection	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Xeljanz	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary

Rinvoq	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Continuous Glucose Monitors (Dexcom G6, FreeStyle Libre)	4/1/2023	Removing PA (moving to Step Therapy)
Kisqali	4/1/2023	Adding to formulary with PA
Verzenio	4/1/2023	Updating criteria defining high-risk for early breast cancer indication
Hyftor	4/1/2023	Adding to formulary with PA
Zoryve	4/1/2023	Adding to formulary with PA

Marketplace Select Plans

Drug/Class	Effective Date	Overview
adapalene/benzoyl peroxide 0.1-2.5%/0.3-2.5% gel	4/1/2023	Removing PA
benznidazole	4/1/2023	Removing PA
Amjevita (adalimumab biosimilar) / Humira	4/1/2023	Adding Amjevita (adalimumab biosimilar) to the formulary with PA; Adding Amjevita to the Humira PA form
Cimzia	4/1/2023	Adding Amjevita (adalimumab biosimilar) for any indications where Cimzia steps through adalimumab with its addition to the formulary
Actemra subq injection	4/1/2023	Adding Amjevita (adalimumab biosimilar) to adalimumab step with its addition to the formulary
Continuous Glucose Monitors (Dexcom G6, FreeStyle Libre)	4/1/2023	Removing PA (moving to Step Therapy)
Kisqali	4/1/2023	Adding to formulary with PA
Verzenio	4/1/2023	Updating criteria defining high-risk for early breast cancer indication
Hyftor	4/1/2023	Adding to formulary with PA
Zoryve	4/1/2023	Adding to formulary with PA